- Home
- / Biogen
Biogen
Stock Price
$183.5
2024-10-29
Market Capitalization
$26.7 B
2024-10-29
Revenue
$9.7 B
FY, 2024
Biogen Summary
Company Summary
- Overview
- Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. It offers medicines and therapies in the areas of lupus, multiple sclerosis, postpartum depression, spinal muscular atrophy, etc.
- Type
- Public
- Status
- Active
- Founded
- 1978
- HQ
- Cambridge, MA, US | view all locations
- Website
- https://www.biogen.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Susan Alexander, Chief Legal Officer and Secretary
Martin Dubuc, Head of Biogen Digital Health
Michael McDonnell, Chief Financial Officer
Operating MetricsView all
Floor Space Owned (RTP, North Carolina), sq. ft.
1M
FY, 2021
Warehouse Facilities Leased (Durham, North Carolina), sq. ft.
65K
FY, 2021
Products (Multiple Sclerosis and Neuroimmunology)
6
FY, 2021
LocationsView all
48 locations detected
Cambridge, MA HQ
United States
225 Binney St
Morrisville, NC
United States
5000 Davis Dr
South San Francisco, CA
United States
6000 Shoreline Ct #304
Washington, DC
United States
701 Pennsylvania Avenue NW #715
Vicente López, Buenos Aires
Argentina
7th Floor, Av. del Libertador 350
Macquarie Park, NSW
Australia
2 Banfield Rd
Biogen Financials
Summary Financials
- Revenue (Q1, 2025)
- $2.4B
- Gross profit (Q1, 2025)
- $1.8B
- Net income (Q1, 2025)
- $240.5M
- Cash (Q1, 2025)
- $2.6B
- Enterprise value
- $30.4B
Competitors and Similar Companies
- Omega TherapeuticsHealthcare - Public
- Cassava SciencesHealthcare - Public
- Fortrea USHealthcare - Subsidiary
- Sanofi GenzymeHealthcare - Subsidiary
- EMD SeronoHealthcare - Private
- GenentechHealthcare - Subsidiary
- NovartisHealthcare - Public
- BayerHealthcare - Public
- AmgenHealthcare - Public
- Gilead SciencesManufacturing & Industrial - Public
- Regeneron PharmaceuticalsHealthcare - Public